Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHarvard Pilgrim Abecma Coverage Policy | OpenPayer
    Ask Trek AI about this page
    CurrentHarvard Pilgrim Health CarePolicy 6763659

    Abecma (idecabtagene vicleucel) for relapsed or refractory multiple myeloma

    Customize your policy alerts

    Sign up for harvard pilgrim health care Policy 6763659 alerts

    Get alerted when Policy 6763659 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage and prior authorization for Abecma, a CAR T-cell therapy, for eligible commercial and specified public-plan members with relapsed or refractory multiple myeloma. It applies to providers requesting treatment in either inpatient or outpatient settings.

    Policy Summary
    PayerHarvard Pilgrim Health Care
    PolicyAbecma (idecabtagene vicleucel) for relapsed or refractory multiple myeloma
    Policy CodePolicy 6763659
    Change TypeAnnual reviewno material clinical or coverage changes
    Effective DateSeptember 1, 2026
    Last ReviewJul 15, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with supporting clinical documentation for Abecma administered in either an inpatient or outpatient setting.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    18+Minimum member age
    2+Required prior lines of therapy
    0-2Required ECOG status
    1 doseMaximum treatment

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Q2055HCPCS code requiring prior authorization
    Inpatient or outpatientAuthorization settings

    Coverage Criteria

    Initial Therapy

    The Plan may cover Abecma for Members aged 18 years or over when all of the following clinical criteria are met:

    ALL of the following

    • The Member is aged 18 years or over.
    • Documentation supports that the Member has a diagnosis of active, measurable multiple myeloma, relapsed or refractory after two (2) or more lines of therapy. This is defined as disease progression after the last treatment regimen or refractory/suboptimal response to the most recent therapy.
    • The Member's previous treatments, unless contraindicated, included all of the following:

      • An immunomodulatory agent (e.g., lenalidomide, pomalidomide).
      • A proteasome inhibitor (e.g., bortezomib, carfilzomib, ixazomib).
      • An anti-CD38 monoclonal antibody (e.g., daratumumab, isatuximab).
    • The Member underwent at least 2 consecutive cycles of treatment for each regimen, unless progressive disease was the best response to the regimen.
    • The Member has had no prior treatment with CAR-T therapy.
    • The Member has adequate organ function, including bone marrow, cardiac, pulmonary, and neurological function, with no anticipated decline in organ function in close proximity to the apheresis timeframe.
    • The Member has no untreated active systemic infection (e.g., viral, bacterial, or fungal), including HIV, active hepatitis B, or active hepatitis C. Screening must be completed at the time of leukapheresis.
    • For Members with a history of allogeneic stem cell transplantation, there is no indication of active graft-versus-host disease (GVHD).
    • The Member has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

    Documentation submitted must list previous lines of treatment/systemic therapies and the date of each therapy. In addition to the criteria above, Abecma may be covered in an outpatient setting when the provider attests that they have assessed the Member and determined that outpatient administration is clinically appropriate. Prior authorization for Abecma is required regardless of whether the treatment is provided in a hospital inpatient or outpatient setting.

    Abecma therapy is contraindicated in pregnancy.

    Members receiving immunosuppressive therapy that is likely (high risk) to interfere with T-cell function will not be approved for Abecma therapy.

    Members with untreated underlying primary immunodeficiency syndromes will not be approved for Abecma therapy.

    Members with active and/or metastatic malignancy that is unlikely to respond to treatment will not be approved for Abecma therapy.

    Authorization of CAR-T therapy is limited to one single-dose treatment. Members who have had prior treatment with any form of CAR-T cell therapy, including therapies in clinical trial settings, will not be approved for additional CAR-T therapy.

    Abecma will not be covered if the Member demonstrates clinical decompensation from the time of authorization to the time of infusion and no longer meets clinical coverage criteria.

    Any indications for CAR-T cell therapy other than those outlined above are considered investigational and will not be covered.

    Initial Abecma Therapy

    Initial Abecma Therapy

    The Plan may cover Abecma for members aged 18 years or over when all of the following clinical criteria are met:

    Initial Abecma eligibility

    • Disease status: Documentation supports active, measurable multiple myeloma that is relapsed or refractory after two or more lines of therapy. Relapsed or refractory disease means progression after the last treatment regimen or a refractory or suboptimal response to the most recent therapy.At least 2 prior lines of therapy
    • Required prior treatment classes: Unless contraindicated, previous treatments included all of the following: an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.All 3 treatment classes

      Examples include lenalidomide or pomalidomide; bortezomib, carfilzomib, or ixazomib; and daratumumab or isatuximab.

    Coding and Billing

    CPT CodesCPT
    No codes listed
    HCPCS CodesHCPCSCovered
    Q2055Idecabtagene vicleucel, up to 460 million autologous B-cell maturation antigen (BCMA) directed CAR-positive T cells, including leukapheresis and dose preparation procedures, per therapeutic dose
    CPT codes with prior authorization removedCPT
    0537TCPT code identified in the revision history; prior authorization was removed effective January 1, 2025.
    0538TCPT code identified in the revision history; prior authorization was removed effective January 1, 2025.
    0539TCPT code identified in the revision history; prior authorization was removed effective January 1, 2025.
    0540TCPT code identified in the revision history; prior authorization was removed effective January 1, 2025.

    Provider Requirements and Coverage Risks

    Prior Authorization

    Prior Authorization Required in All Settings

    Prior authorization is required for Abecma regardless of site of administration. Submit supporting clinical documentation with the request before treatment, whether administration is planned in the hospital inpatient or outpatient setting.

    • Applies to both inpatient and outpatient administration.
    • Supporting clinical documentation is required when submitting the service request.
    Billing Rule

    Authorization and Coding History

    Obtain authorization before treatment and apply the policy’s current coding requirements. The policy’s December 2024 revision removed prior authorization from CPT codes 0537T, 0538T, 0539T, and 0540T effective January 1, 2025; this coding change does not remove the policy’s requirement for authorization of Abecma therapy itself.

    Therapy Background

    CAR T-cell therapy begins with apheresis, which removes the patient's T cells. The cells are then genetically engineered to express chimeric antigen receptors, expanded, and reinfused to target malignant cells. Abecma is used for certain hematologic malignancies, including eligible adults with relapsed or refractory multiple myeloma after the required prior therapy.

    Clinical Definitions

    ECOG Performance Status
    ECOG 0Fully active, with no restrictions on activities.
    ECOG 1Unable to do strenuous activities, but able to carry out light housework and sedentary activities.
    ECOG 2Able to walk and manage self-care, but unable to work; out of bed more than 50% of waking hours.
    Relapsed or Refractory Multiple Myeloma
    Disease statusActive, measurable multiple myeloma that is relapsed or refractory after two or more lines of therapy.
    Relapsed diseaseDisease progression after the last treatment regimen.
    Refractory disease

    Quantity Limit

    Quantity Limits
    DrugAbecma
    Authorization limitOne single-dose treatment.
    Treatment basisPer course, as one therapeutic dose.

    Administration Setting

    Documentation Required

    Office administration requires attestation

    Outpatient administration may be covered when the provider attests that the member has been assessed and that outpatient administration is clinically appropriate. Prior authorization remains required for outpatient administration.

    Prior Authorization

    Authorize hospital administration

    Prior authorization is required for Abecma administered in a hospital inpatient setting. The policy requires authorization regardless of whether administration occurs in an inpatient or outpatient setting.

    Policy Summary
    PayerHarvard Pilgrim Health Care
    PolicyAbecma (idecabtagene vicleucel) for relapsed or refractory multiple myeloma
    Policy CodePolicy 6763659
    Change TypeAnnual reviewno material clinical or coverage changes
    Effective DateSeptember 1, 2026
    Last ReviewJul 15, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with supporting clinical documentation for Abecma administered in either an inpatient or outpatient setting.
    SourceLink
    On This Page
    Coverage CriteriaInitial Abecma TherapyCoding and BillingProvider Requirements and Coverage RisksTherapy BackgroundClinical DefinitionsQuantity LimitAdministration Setting
    Treatment exposure: The member underwent at least 2 consecutive cycles of treatment for each regimen, unless progressive disease was the best response to that regimen.At least 2 consecutive cycles per regimen, unless progressive disease was the best response
  1. CAR-T treatment history: The member has had no prior treatment with CAR-T therapy.No prior CAR-T therapy
  2. Organ function: The member has adequate bone marrow, cardiac, pulmonary, and neurological function, with no anticipated decline in organ function in close proximity to the apheresis timeframe.Adequate function in all listed organ systems
  3. Infection screening: The member has no untreated active systemic infection, including viral, bacterial, or fungal infection, HIV, active hepatitis B, or active hepatitis C. Screening must be completed at the time of leukapheresis.No untreated active systemic infection; screening at leukapheresis
  4. Allogeneic transplant history: For a member with a history of allogeneic stem cell transplantation, there is no indication of active graft-versus-host disease (GVHD).No active GVHD when applicable
  5. Functional status: The member has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.ECOG 0–2
    • Confirm authorization requirements for the specific service and date of service.
    • Use current coding and claims-editing guidance; coverage remains subject to eligibility, benefits, referral/authorization, utilization management, and plan procedures.
    Prior Authorization

    EPSDT Coverage Still Requires Authorization

    For Tufts Health Together (Medicaid), coverage may be available beyond these guidelines for pediatric members under age 21 through EPSDT when medically appropriate and covered under the plan. Prior authorization remains required.

    • Applies to pediatric members under age 21.
    • Review 130 CMR 450.140 and 130 CMR 447.000 and obtain prior authorization.

    Unsupported block type: documentationос

    Unsupported block type: documentationоз

    Unsupported block type: documentation울

    Denial Risk

    Contraindications and Noncovered Circumstances

    Do not request or administer Abecma when a listed contraindication or noncovered circumstance applies. The policy excludes pregnancy, high-risk immunosuppressive therapy likely to interfere with T-cell function, untreated primary immunodeficiency, active or metastatic malignancy unlikely to respond, prior CAR-T therapy, and indications outside the defined criteria.

    • Authorization is limited to one single-dose CAR-T treatment.
    • Do not approve additional CAR-T therapy after any prior CAR-T treatment, including treatment in a clinical trial.
    • Do not proceed if the Member clinically decompensates after authorization and no longer meets coverage criteria.
    • Indications other than those outlined in the policy are investigational and not covered.
    Denial Risk

    Failure to Meet Clinical Criteria Risks Denial

    Failure to satisfy any required clinical criterion may result in nonapproval or denial. Before authorization and infusion, verify diagnosis and prior therapy, adequate organ function, infection screening, transplant/GVHD status, ECOG performance status, and the absence of prior CAR-T therapy and other exclusions.

    • Confirm active, measurable relapsed or refractory multiple myeloma after two or more lines of therapy.
    • Confirm required prior treatment classes and treatment-cycle history, or document contraindication or progressive disease as the best response.
    • Confirm no untreated active systemic infection and no anticipated organ-function decline near apheresis.
    • Reassess coverage criteria if the Member’s condition changes between authorization and infusion.
    A refractory or suboptimal response to the most recent therapy.